



Curriculum Vitae

Personal information Fakhredin Sayed Tabatabaei

Work experience

1. Employer: Ministry of Health, Welfare and Sport
 - Start date: 2006
 - End date:
 - Position: Senior Assessor Pharmacovigilance
 - Activities:
 - Country: Netherlands
2. Employer: European Medicines Agency
 - Start date: 042009
 - End date: 122009
 - Position: Detached National Expert in Pharmacovigilance
 - Activities:
 - Country: United Kingdom
3. Employer: Erasmus Medical Centre, Rotterdam
 - Start date: 2001
 - End date: 2006
 - Position: Researcher
 - Activities:
 - Country: Netherlands
4. Employer: Isfahan Cardiovascular Research Centre
 - Start date: 1997
 - End date: 2000
 - Position: Medical practitioner, Researcher
 - Activities:
 - Country: Iran

Education and training

1. Subject: Erasmus University Rotterdam
 - Start date: 2001
 - End date: 2005
 - Qualification: Doctor of Philosophy (PhD)
 - Organisation:
 - Country: Netherlands
2. Subject: Erasmus University Rotterdam
 - Start date: 2000
 - End date: 2001
 - Qualification: Master of Science (MSc)
 - Organisation:
 - Country: Netherlands
3. Subject: Isfahan University of Medical Sciences
 - Start date: 1988
 - End date: 1996
 - Qualification: Doctor of Medicine (MD)
 - Organisation:
 - Country: Iran
4. Subject: HL7 Netherlands
 - Start date: 032022
 - End date: 032022
 - Qualification: HL7 FHIR training
 - Organisation:
 - Country: Netherlands

Additional information

Publications

Rosilane de Aquino Silva, Juan Garcia Burgos, F.A. Sayed Tabatabaei, Teruyoshi Ehara, Tomoko Osawa, Mai Okamoto, Yousef S. Al_Amri, Bashayer K. Albalkhi, Stephan Jaermann, Irmgard Schmitt_Koopmann, Chyn_Liang Huang, Po_Wen Yang, Lih_Jia Huang, Miao_Ju Chien, Yu_Ting Chiu, Tony Manderson. Electronic product information for human medicines: The current situation and future projections based on a cross_sectional survey. Submitted.

Zomerdijk IM, Trifirò G, Sayed_Tabatabaei FA, Sturkenboom MC, Straus SM. Additional risk minimisation measures in the EU- are they eligible for assessment? *Pharmacoepidemiol Drug Saf.* 2013 Aug [Epub 2013 Aug 15].

Ebbers HC, Mantel_Teeuwisse AK, Moors EHM, Sayed_Tabatabaei FA, Schellekens H, Leufkens HGM. The Role of Periodic Safety Update Report Assessments in the Safety Management of Biopharmaceuticals. *Eur J Clin Pharmacol.* 2013 Feb;69(2):217_426.

Ebbers HC, Mantel_Teeuwisse AK, Moors EHM, Sayed_Tabatabaei FA, Schellekens H, Leufkens HGM. A Cohort Study Exploring Determinants of Safety Related Regulatory Actions for Biopharmaceuticals. *Drug Saf.* 2012;35:417_427.

Zomerdijk IM, Sayed_Tabatabaei FA, Trifirò G, Blackburn SCF, Sturkenboom MCJM, Straus SMJM. Risk Minimisation

Activities of Centrally Authorised Products in the EU: A descriptive study. *Drug Saf.* 2012;35:299_314.

Blik BJ, van Schaik RH, van der Heiden IP, Sayed_Tabatabaei FA, van Duijn CM, Steegers EA, Steegers_Theunissen RP. Eurocran Gene_Environment Interaction Group. Maternal medication use, carriage of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. *Am J Med Genet A.* 2009;149A:2088_2092.

Coppus AM, Evenhuis HM, Verberne GJ, Visser FE, Arias_Vasquez A, Sayed_Tabatabaei FA, Vergeer_Drop J, Eikelenboom P, van Gool WA, van Duijn CM. The impact of apolipoprotein E on dementia in persons with Down's syndrome. *Neurobiol Aging.* 2008;29:828_835.

van de Garde EM, Endeman H, Deneer VH, Biesma DH, Sayed_Tabatabaei FA, Ruven HJ, Leufkens HG, van den Bosch JM. Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. *Chest.* 2008;133:220_225.

Boccia S, Cadoni G, Sayed_Tabatabaei FA, Volante M, Arzani D, De Lauretis A, Cattel C, Almadori G, van Duijn CM, Paludetti G, Ricciardi G. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit anneck cancer. *J Cancer Res Clin Oncol.* 2008;134:93_100.

Verkleij_Hagoort A, Blik J, Sayed_Tabatabaei F, Ursem N, Steegers E, Steegers_Theunissen R. Hyperhomocysteinemia and MTHFR polymorphisms in association with orofacial clefts and congenital heart defects: a meta_analysis. *Am J Med Genet A.* 2007;143:952_960.

Boccia S, Sayed_Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, La Greca A, D'Ugo D, La Torre G, van Duijn CM, Ricciardi G. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastritis in Italian population. *BMC Cancer.* 2007;7:206.

Yazdanpanah M, Aulchenko YS, Hofman A, Janssen JA, Sayed_Tabatabaei FA, van Schaik RH, Klungel OH, Stricker BH, Pols HA, Witteman JC, Lamberts SW, Oostra BA, van Duijn CM. Effects of the renin_angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes. *Diabetes.* 2007;56:1905_1912.

Isaacs A, Aulchenko YS, Hofman A, Sijbrands EJ, Sayed_Tabatabaei FA, Klungel OH, Maitland_van der Zee AH, Stricker BH, Oostra BA, Witteman JC, van Duijn CM. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high_density lipoprotein cholesterol levels. *J Clin Endocrinol Metab.* 2007;92:2680_2687.

Isaacs A, Sayed_Tabatabaei FA, Hofman A, Oostra BA, Klungel OH, Maitland_Vander Zee AH, Stricker BH, Witteman JC, van Duijn CM. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high_density lipoprotein levels and decreased risk of myocardial infarction: the Rotterdam Study. *Eur J Cardiovasc Prev Rehabil.* 2007;14:419_421.

van Rijn MJ, Schut AF, Aulchenko YS, Deinum J, Sayed_Tabatabaei FA, Yazdanpanah M, Isaacs A, Axenovich TI, Zorkoltseva IV, Zillikens MC, Pols HA, Witteman JC, Oostra BA, van Duijn CM. Heritability of blood pressure traits and the genetic contribution to blood pressure variance explained by four blood_pressure_related genes. *J Hypertens.* 2007;25:565_570.

Isaacs A, Sayed_Tabatabaei FA, Aulchenko YS, Zillikens MC, Sijbrands EJ, Schut AF, Rutten WP, Pols HA, Witteman JC, Oostra BA, van Duijn CM. Heritabilities, apolipoprotein E, and effects of inbreeding on plasma lipids in a genetically isolated population: the Erasmus Rucphen Family Study. *Eur J Epidemiol.* 2007;22:99_105.

Yazdanpanah M, Sayed_Tabatabaei FA, Janssen JA, Rietveld I, Hofman A, Stijnen T, Pols HA, Lamberts SW, Witteman JC, van Duijn CM. IGF_I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. *Eur J Endocrinol.* 2006;155:751_756.

Yazdanpanah M, Sayed_Tabatabaei FA, Hofman A, Aulchenko YS, Oostra BA, Stricker BH, Pols HA, Lamberts SW, Witteman JC, Janssen JA, van Duijn CM. The alpha_adducin gene is associated with macrovascular complications and mortality in patients with type 2 diabetes. *Diabetes.* 2006;55:2922_2927.

Sayed_Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JCM. ACE polymorphisms. *Circ Res.* 2006;98:1123_1133. Review.

Sie MPS, Sayed_Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HAP, Hofman A, van Duijn CM, Witteman JCM. The Interleukin 6 -174 G/C promoter polymorphism and risk of coronary heart disease: results from the Rotterdam Study and a meta_analysis. *Arterioscler Thromb Vasc Biol.* 2006; 26:212_217.

Sayed_Tabatabaei FA, van Rijn MJE, Schut AF, Aulchenko YS, Croes EA, Zillekens MC, Pols HAP, Witteman JC, Oostra BA, van Duijn CM. Heritability of function and structure of the arterial wall: findings in the Erasmus Rucphen Family (ERF) study. *Stroke.* 2005;36:2351_2356.

Oei HH, Sayed_Tabatabaei FA, Hofman A, Oudkerk M, van Duijn CM, Witteman JC. The association between angiotensin_converting enzyme gene polymorphism and coronary calcification, The Rotterdam Coronary Calcification Study. *Atherosclerosis.* 2005;182:169_173.

González_Zuloeta Ladd AM, Arias_Vásquez A, Sayed_Tabatabaei FA, Coebergh JW, Hofman A, Njajou OT, Stricker B, van Duijn CM. Angiotensin converting enzyme gene insertion/deletion polymorphism and breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2005;14:2143_2146.

Arias_Vásquez A, Sayed_Tabatabaei FA, Schut AF, Hofman A, Bertoli_Avella AM, Vergeer J, Aulchenko YS, Witteman JC, van Duijn CM. Angiotensin converting enzyme gene, smoking and mortality in a population_based study. *Eur J Clin Invest.* 2005;35:444_449.

López León S, Croes EA, Sayed_Tabatabaei FA, Claes S, van Broeckhoven C, van Duijn CM. The Dopamine D4 receptor gene 48_basepair_repeat polymorphism and mood disorders: a meta_analysis. *Biol Psychiatry.* 2005;57:999_1003.

Sayed_Tabatabaei FA, Schut AF, Arias_Vásquez A, Bertoli_Avella AM, Hofman A, Witteman JC, van Duijn CM. Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. *J Med Genet.* 2005;42:26_30.

Isaacs A, Sayed_Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM. The _514 C_>T hepatic lipase promoter region polymorphism and plasma lipids: a meta_analysis. *J Clin Endocrinol Metab.* 2004;89:3858_3863.

Mattace_Raso FUS, van der Cammen TJM, Sayed_Tabatabaei FA, van Popele NM, Asmar R, Schalekamp MADH, Hofman A, van Duijn CM, Witteman JC. Angiotensin_converting enzyme gene polymorphism and common carotid stiffness, The Rotterdam study. *Atherosclerosis.* 2004;174:121-126.

Schut AF, Sayed_Tabatabaei FA, Witteman JC, Avella AM, Vergeer JM, Pols HA, Hofman A, Deinum J, van Duijn CM. Smoking_dependent effects of the angiotensin_converting enzyme gene insertion/deletion polymorphism on blood pressure. *J Hypertens.* 2004;22:313_319.

Sayed_Tabatabaei FA, Schut AF, Hofman A, Bertoli_Avella AM, Vergeer J, Witteman JC, van Duijn CM. A study of gene_environment interaction on the gene for angiotensin converting enzyme: a combined functional and population

based approach. J Med Genet. 2004;41:99_ 103.

Sayed_Tabatabaei FA, Houwing_Duistermaat JJ, van Duijn CM, Witteman JC. Angiotensin_converting enzyme gene polymorphism and carotid artery wall thickness: a meta_analysis. Stroke. 2003;34:1634_1639.

Sarrafi_Zadegan N, Boshtam M, Malekafzali H, Bashardoost N, Sayed_Tabatabaei FA, Rafiei M, Khalili A, Mostafavi S, Khami M, Hassanvand R. Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. Acta Cardiol. 1999;54:327_333.

Sarrafi_Zadegan N, Sayed_Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, Sotodehmaram E, Tafazoli F, Karimi A. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol. 1999;54:257_263.

Sayed_Tabatabaei FA. The level of smokers' desire to quit in Isfahan city. South Asian J Preventive Cardiology. 1998;2:106_108.

Projects

Product Management Services (PMS) Subject Matter Expert 2022 _ current

CBG_MEB renewing the business core_system 2022 _ current

EC_EMA_HMA ePI (electronic Product Information) 2018 _ current

CMDh HaRP (Harmonisation of RMP Project) 2017 _ current

Memberships

Other Relevant Information

TEACHING EXPERIENCE DIA: DIA/MEB Excellence in Pharmacovigilance (2018 _ current)

EU2P: European Programme in Pharmacovigilance and Pharmacoepidemiology. Master in Pharmacovigilance and Pharmacoepidemiology (via e_learning platform) (2011).

Top Institute Pharma (TI Pharma). Drug Discovery & Development Cycle (2008 – 2011)

Netherlands Institute for Health Sciences (NIHES), Erasmus Medical Centre. Study Design / Genetic_epidemiologic Research Methods / Principles of Genetic Epidemiology (2002 – 2005)